Opioids Could Become Bioterror Weapons, US Fears; BARDA Funds Countermeasures

Opiant could get $4.6m to accelerate development of nasal nalmefene for treatment of opioid overdose.

Medical advice and medication guidance and prescription drugs health consultation as a giant pill shaped as a lighthouse beacon with 3D illustration elements.

Opiant Pharmaceuticals Inc. is benefiting from the government's desire to develop treatments for possible terrorist attacks involving fentanyl or other opioids.

The Biomedical Advanced Research and Development Authority (BARDA), part of HHS's Office of the Assistant Secretary for Preparedness and Response,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from R&D

More from Pink Sheet